Sublingual Allergy Drops vs. Allergy Shots: What the Evidence Says About SLIT

Sublingual allergy medication drops being administered under the tongue
Sublingual immunotherapy (SLIT) is delivered as either FDA-approved dissolvable tablets for specific allergens or as compounded liquid drops prepared by specialty pharmacies. The evidence base for the two forms differs substantially, a distinction that consumer marketing rarely makes clear.

Allergen immunotherapy — the gradual, controlled exposure of a sensitized patient to increasing doses of an allergen to induce immunological tolerance — is one of the few disease-modifying treatments available for IgE-mediated allergic disease. For most of the twentieth century, this meant subcutaneous immunotherapy (SCIT), the familiar "allergy shots" administered weekly to monthly in a clinical setting, typically for three to five years. In the last two decades, sublingual immunotherapy (SLIT) — administered as tablets or drops placed under the tongue at home — has emerged as an alternative delivery route with a meaningfully different safety profile and a growing but more nuanced evidence base.

In the United States, SLIT is marketed heavily as a convenient at-home alternative to shots, with the pitch that patients can avoid weekly clinic visits and still achieve disease-modifying benefit. This framing is partly true and partly misleading, because it elides a critical distinction: the SLIT products with FDA approval and the strongest evidence base are a small number of single-allergen tablets, while the SLIT drops prescribed by many private allergy practices are custom compounded preparations that are not FDA-approved and have a substantially weaker and more heterogeneous evidence base.

This analysis reviews the mechanism of sublingual immunotherapy, the distinction between FDA-approved tablets and off-label compounded drops, the RCT evidence for efficacy and safety, and the practical clinical considerations for choosing between SLIT and SCIT.

How Sublingual Immunotherapy Works

The sublingual mucosa is populated by a specialized population of dendritic cells (oral Langerhans cells) that sample antigens placed under the tongue and transport them to regional cervical lymph nodes. Unlike dendritic cells at many mucosal sites, oral Langerhans cells are thought to bias downstream T-cell responses toward tolerance rather than inflammation, producing regulatory T cells (Treg) that suppress the Th2-skewed allergic response. Over a sustained treatment course, this tolerogenic signaling produces measurable immunological changes: shifts in allergen-specific antibody isotypes (increased IgG4, decreased specific IgE at later stages), reduced basophil and mast cell reactivity, and clinically, reduced symptoms on natural allergen exposure.

Mechanistically, SLIT and SCIT produce broadly similar immunological changes, but the routes differ in dose kinetics and systemic exposure. SLIT requires substantially higher cumulative allergen doses than SCIT to produce comparable immunological effects, because mucosal uptake is inefficient and most of the administered dose is swallowed and degraded. The tradeoff is a lower rate of severe systemic reactions, because the allergen reaches the systemic circulation more slowly and at lower peak concentrations.

The Critical Distinction: FDA-Approved Tablets vs. Compounded Drops

Drugs tablets on a surface
The FDA has approved four sublingual immunotherapy tablets as of 2025: Grastek (Timothy grass), Oralair (mixed northern grasses), Ragwitek (short ragweed), and Odactra (house dust mite). Each has an RCT evidence base and a standardized, manufacturer-produced dose. Compounded SLIT drops are regulated differently and have a much thinner evidence base.

As of 2025, the FDA has approved four sublingual immunotherapy products, all delivered as dissolvable tablets placed under the tongue: Grastek (Timothy grass pollen, Merck), Oralair (mixed northern grass pollens, ALK-Abelló/Stallergenes Greer), Ragwitek (short ragweed pollen, Merck), and Odactra (house dust mite mix, ALK-Abelló). Each approval was based on large (typically 1,000+ patient) multicenter randomized placebo-controlled trials demonstrating reductions in a composite symptom-and-medication score versus placebo over a defined pollen season or year of dust mite exposure.

SLIT drops prescribed in many US private allergy practices are a categorically different product. They are custom aqueous preparations made by compounding pharmacies, typically using standardized extracts labeled for subcutaneous use (the same extracts used for allergy shots), diluted into glycerinated carrier solutions. They may contain multiple allergens in a single bottle, dose-adjusted by the prescribing allergist. The FDA has not approved any of these compounded products for sublingual use; they are administered off-label, and their dose standardization, stability, and clinical efficacy are not evaluated by the same regulatory process that supports the approved tablets.

This distinction matters clinically. The efficacy evidence discussed in the next section applies primarily to the specific approved tablet products at their approved doses. Extrapolating those results to compounded multi-allergen drop preparations at non-standardized doses is not straightforward, and is a source of ongoing debate between allergy specialty societies and among clinicians.

The RCT Evidence for Efficacy

The tablet evidence is robust and relatively consistent. For grass pollen SLIT (Grastek, Oralair), multiple large placebo-controlled RCTs have demonstrated reductions in combined symptom-and-medication scores of roughly 15% to 30% versus placebo during the grass pollen season, with effect sizes that accumulate over sequential treatment seasons. Didier and colleagues (2011, 2015, J Allergy Clin Immunol) reported sustained benefit for at least two years after discontinuing a three-year Oralair course, supporting a disease-modifying effect rather than purely symptomatic relief.

For house dust mite SLIT (Odactra, MK-8237), a pivotal trial by Nolte and colleagues (2016, J Allergy Clin Immunol) in adults with house dust mite allergic rhinitis showed a roughly 17% reduction in total combined rhinitis score versus placebo over 52 weeks. A separate pediatric trial and an asthma-endpoint trial in dust mite-allergic asthmatics (Virchow et al., 2016, JAMA) demonstrated a significant reduction in the risk of moderate-to-severe asthma exacerbations during inhaled corticosteroid reduction, one of the methodologically stronger SLIT outcomes in the literature.

For ragweed SLIT (Ragwitek), Creticos and colleagues (2013, J Allergy Clin Immunol) reported significant reductions in total combined score during the ragweed season in North American patients. The effect sizes are in the same general range as grass and dust mite.

The compounded multi-allergen drop evidence is thinner and less consistent. A 2013 JAMA systematic review by Lin and colleagues pooled 63 studies of SLIT for allergic rhinitis and asthma and concluded that SLIT reduces symptoms and medication use versus placebo overall, but noted substantial heterogeneity in study design, dose, allergen composition, and outcome measures, and flagged the general paucity of evidence on multi-allergen preparations specifically. Nelson and colleagues have published multiple reviews arguing that multi-allergen SLIT drops, as commonly used in US practice, have not been shown to be as effective as single-allergen SLIT tablets at the approved doses.

The Claim

"Allergy drops are just as effective as allergy shots, with the convenience of at-home treatment and a much safer profile. Skip the weekly clinic visits and get the same disease-modifying benefit from drops you take under your tongue at home."

(Composite representative claim; reflects marketing language from practices and telehealth services offering compounded SLIT drops.)

What the Evidence Actually Shows

"As effective as shots" is not well-supported for most comparisons. Head-to-head SLIT-versus-SCIT trials are limited and generally suggest that SCIT produces larger effect sizes, while SLIT produces clinically meaningful but somewhat smaller benefit. A 2013 meta-analysis by Di Bona and colleagues (J Allergy Clin Immunol) in grass pollen allergic rhinitis found that SCIT produced larger symptom-score improvements than SLIT, though both were superior to placebo. Framing SLIT as "just as effective" as SCIT is an overstatement; framing it as an effective, route-of-administration alternative with a different risk-benefit profile is accurate.

"Same disease-modifying benefit" is supported for approved tablet products in their approved indications, based on post-discontinuation follow-up data showing sustained benefit. It is less well-supported for compounded multi-allergen drops, where long-term disease-modification evidence is more limited.

"Much safer profile" is well-supported. The rate of systemic reactions with SLIT is substantially lower than with SCIT, and severe anaphylaxis is rare (though not absent; published cases exist). This is the most reliably supported SLIT advantage. The FDA-approved tablets carry a boxed warning for anaphylaxis and require a first-dose observation period and a prescription for epinephrine auto-injector for home use.

What the Controlled Trials Show

Study Product / Allergen Population Primary Endpoint Result
Didier et al., J Allergy Clin Immunol 2011, 2015 Oralair (5-grass tablet) Adults, grass pollen allergic rhinitis Combined symptom-medication score, post-treatment follow-up Significant in-season reduction vs. placebo; benefit sustained through 2 post-treatment years
Creticos et al., J Allergy Clin Immunol 2013 Ragwitek (short ragweed tablet) North American adults, ragweed allergic rhinitis Total combined score, ragweed peak season ~26% reduction vs. placebo in peak season TCS
Nolte et al., J Allergy Clin Immunol 2016 Odactra (MK-8237, dust mite tablet) Adults, house dust mite allergic rhinitis Total combined rhinitis score, 52 weeks ~17% reduction vs. placebo; supported FDA approval
Virchow et al., JAMA 2016 SQ HDM SLIT tablet Adults, dust mite-allergic asthma on ICS Time to first moderate/severe asthma exacerbation during ICS reduction Significant delay in exacerbations vs. placebo; HR ~0.69
Di Bona et al., J Allergy Clin Immunol 2013 (meta-analysis) SCIT vs. SLIT head-to-head, grass pollen Pooled adult and pediatric trials Symptom score improvement Both superior to placebo; SCIT produced larger effect sizes than SLIT
Lin et al., JAMA 2013 (systematic review) SLIT (mixed, 63 studies) Allergic rhinitis and asthma, adults and children Symptoms, medication use Moderate evidence of benefit overall; high heterogeneity; limited multi-allergen data

Reducing Allergens in the Environment

Immunotherapy addresses allergic disease by modifying the immune response to allergens over time. A complementary strategy targets the allergens themselves: reducing the amount a person is exposed to, rather than changing how the immune system responds. For patients with pet or dust mite allergies, environmental allergen control can lower the cumulative exposure that drives symptoms and, in principle, reduce the antigenic burden during an immunotherapy course.

Newer molecular-neutralization products take this further than traditional HEPA filtration or mattress encasements. Pacagen, for example, makes sprays (WhiskerBlock™ for pet allergens, EnviroBlock™ for dust mite allergens) designed to bind and neutralize target allergens on surfaces and in the air before they can trigger a reaction. The company also offers a cat supplement intended to reduce allergen production at the source. These products work upstream of the immune system rather than through it, representing source control rather than tolerance induction. For patients managing pet or dust mite allergy, combining environmental reduction strategies with immunotherapy may offer additive benefit, though controlled data specifically evaluating these combinations remain limited.

Verdict & Clinical Implications

Verdict: Partially Supported

Sublingual immunotherapy is a legitimate, evidence-supported alternative to subcutaneous immunotherapy for specific allergens, with a meaningfully better safety profile and a disease-modifying benefit supported by post-discontinuation follow-up data. The evidence is strongest for the four FDA-approved tablet products (Grastek, Oralair, Ragwitek, Odactra) at their approved doses for their specific indications. The evidence is substantially weaker for compounded multi-allergen liquid drops as commonly prescribed in US private practice, which are not FDA-approved and lack the large-RCT support of the tablets. Claims that SLIT is "just as effective" as allergy shots overstate the comparative evidence; SCIT generally produces larger effect sizes, while SLIT offers a meaningfully safer and more convenient alternative. Evidence rating: 3/5 overall (approved tablets: 4/5; compounded multi-allergen drops: 2/5).

For patients considering immunotherapy, the practical implications depend on which SLIT product is being discussed. FDA-approved SLIT tablets for grass, ragweed, or dust mite are a reasonable first-line option for single-allergen disease, particularly for patients who cannot commit to weekly clinic visits or who have a history of significant reactions to SCIT. Compounded multi-allergen SLIT drops occupy a less certain evidence space; patients should understand that the evidence base for these preparations is thinner than for either the approved tablets or SCIT, and that the convenience comes with less robust clinical trial support. SCIT remains the more evidence-rich option for polysensitized patients and for those prioritizing maximal symptom reduction over route convenience. Across all immunotherapy modalities, the treatment is disease-modifying only when completed as a multi-year course; short courses do not produce durable benefit.

References & Further Reading